Results 261 to 270 of about 28,689 (318)

Response to two Janus kinase inhibitors in a boy with SAVI during 2-year follow-up: case report and literature review. [PDF]

Front Immunol
Chen Y, Zang W, Zhong H, Deng X, Zhong W, Wang L, Chen X.   +6 more
europepmc   +1 more source

Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)

, 2018
Raajit K. Rampal, John Mascarenhas, Heidi E. Kosiorek, Rupali Bhave, Elizabeth O. Hexner, Eunice S. Wang, Aaron T. Gerds, Mark Heaney, Camille N. Abboud, Marina Kremyanskaya, Dmitriy Berenzon, Olatoyosi Odenike, Elizabeth Virtgaym, Lonette Sandy, Rona Singer Weinberg, Vesna Najfeld, Mohamed E. Salama, Ross L. Levine, Ruben A. Mesa, Amylou C. Dueck, Ronald Hoffman   +20 more
openalex   +1 more source

Treatment of refractory Hailey-Hailey disease with oral upadacitinib and topical ruxolitinib 1.5% cream. [PDF]

JAAD Case Rep
Alhwayek G, Sanders M, Farley V.
europepmc   +1 more source

Momelotinib for myelofibrosis. [PDF]

Aust Prescr
europepmc   +1 more source

Efficacy and safety of ruxolitinib in adult patients with refractory rheumatic disease-associated macrophage activation syndrome. [PDF]

Front Immunol
Li J, Wang R, Chen J, Xu A, Fu Y, Lin Y, Wang X, Ye S, Yuan Y, Du F, Fu Q.   +10 more
europepmc   +1 more source

Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review. [PDF]

Dermatol Ther (Heidelb)
Sanchez K, Englander H, Salloum L, Gregoire S, Biba U, Ershadi S, Mostaghimi A.   +6 more
europepmc   +1 more source

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study. [PDF]

J Clin Oncol
Zeiser R, Russo D, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hamad N, Burock K, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F.   +16 more
europepmc   +1 more source

Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study.

Acta Haematol
Al-Ali HK, Guglielmelli P, Harrison CN, Mesa RA, Hamer-Maansson JE, Braunstein E, Gupta V.   +6 more
europepmc   +1 more source

A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database. [PDF]

Ann Hematol
Reeves BN, Masarova L, Abu-Zeinah G, Hunter AM, Shatzel JJ, Qin A, Yoon CH, Cai LY, Wei YF, Mesa RA.   +9 more
europepmc   +1 more source

Efficacy and Safety of Momelotinib in Myelofibrosis: A Systematic Review and Meta-Analysis With a Focus on Anemia Outcomes. [PDF]

J Hematol
Al-Nusair J, Aldalal'ah M, Alqudah M, Al-Malkawi F, Al-Khateeb N, Khasawneh H, El-Shatel O, Khayyat O, Alseid SH, Abdallah M, Soudah O, Pacioles T, Jamil MO.   +12 more
europepmc   +1 more source